US Pre-Market SEC Filings Roundup — February 25, 2026

26-02-2026

Titan International Inc filed an 8-K on February 26, 2026 (AccNo: 0000899751-26-000009, Size: 632 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This constitutes a multi-item filing announcing financial results. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing summary.

• ·AccNo: 0000899751-26-000009
• ·File Size: 632 KB
• ·Event Type: Financial Results
• ·Source: us_sec

26-02-2026

ZIFF DAVIS, INC. filed an 8-K on February 26, 2026, specifically under Item 7.01 for Regulation FD Disclosure, with Accession Number 0001084048-26-000007 and file size of 140 KB. No financial metrics, transaction details, quantitative data, positive or negative performance indicators, scheduled events, or other specific content are disclosed in the provided filing information. This is a single-item voluntary filing with no mentioned market or strategic impacts.

26-02-2026

Donaldson Co Inc filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative financial metrics were disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data.

26-02-2026

Carriage Services Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no quantitative financial metrics available.

26-02-2026

Immunic, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193805-26-000181), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were mentioned in the provided filing information.

26-02-2026

Lindblad Expeditions Holdings, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001437749-26-005736), reporting under Item 2.02 Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. This constitutes a multi-item filing disclosing the company's financial results, likely including a press release and tables as exhibits. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics were explicitly stated in the provided filing details.

26-02-2026

Gibraltar Industries, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information. No positive or negative performance details, scheduled events, or strategic updates were mentioned.

26-02-2026

Gray Media, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001437749-26-005740), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet impacts, guidance, or period-over-period metrics are mentioned in the provided filing details. This represents a standard voluntary earnings-related disclosure without quantified financial data.

26-02-2026

International Seaways, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001104659-26-020057), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results in the US equity markets. No specific financial metrics, period-over-period comparisons, or other quantitative details are provided in the available filing information.

26-02-2026

Papa Johns International Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011964), furnishing information under Item 2.02 regarding results of operations and financial condition, and under Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing details. This is a standard earnings-related disclosure with no quantitative metrics available.

26-02-2026

Biocryst Pharmaceuticals Inc. filed a Form 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing related to financial results with AccNo 0001171843-26-001119 and file size 435 KB. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the provided filing information.

26-02-2026

Cronos Group Inc. filed a Form 8-K on 2026-02-26 (AccNo: 0001656472-26-000015, Size: 978 KB) reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, positive metrics, negative metrics, or flat performance details are disclosed. This appears to be a standard voluntary earnings-related disclosure.

• ·AccNo: 0001656472-26-000015
• ·File size: 978 KB
• ·Event Type: Financial Results
• ·Sector: NOT_DISCLOSED

26-02-2026

Cheniere Energy, Inc. filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, or other quantitative details are provided in the filing summary. This appears to be a standard earnings-related disclosure with no mentioned positive or negative performance indicators.

• ·AccNo: 0000003570-26-000006
• ·Filing size: 575 KB

26-02-2026

26-02-2026

26-02-2026

Privia Health Group, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached financial statements.

26-02-2026

Fortrea Holdings Inc. filed an 8-K on 2026-02-26 reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.

• ·Filing Accession Number: 0001628280-26-011942
• ·Filing Size: 440 KB
• ·Event Type: Financial Results
• ·Sector: NOT_DISCLOSED

26-02-2026

Primo Brands Corp filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, guidance, or other quantitative metrics are disclosed in the provided filing information. No positive or negative performance indicators, period-over-period comparisons, or strategic details are mentioned.

26-02-2026

BeOne Medicines Ltd. filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-011941), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons were disclosed in the filing summary. The filing size is 2 MB, with sector not specified.

26-02-2026

Arhaus, Inc. filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits), announcing financial results. This is a multi-item voluntary disclosure typical for earnings releases. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information.

26-02-2026

Qnity Electronics, Inc. filed a Form 8-K on February 26, 2026, disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are mentioned in the provided filing details. This appears to be a standard mandatory earnings-related disclosure with attached exhibits.

• ·Filing Accession Number: 0002058873-26-000007
• ·Filing Size: 681 KB
• ·Sector: NOT_DISCLOSED

26-02-2026

First Advantage Corp filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073071), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No revenue, earnings, margins, guidance, period-over-period changes, or other quantitative financial metrics were explicitly stated in the filing description. This is a standard voluntary disclosure of financial results without detailed data provided.

• ·File size: 1 MB

26-02-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. Critical event content is missing, limiting assessment of impact.

26-02-2026

Walker & Dunlop, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet effects, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item earnings-related disclosure with no detailed performance data available.

26-02-2026

Norris Industries, Inc. filed an 8-K on February 26, 2026, specifically reporting Item 4.01 Changes in Registrant's Certifying Accountant. No financial metrics, transaction values, reasons for the change, names of prior or new accountants, or other details were disclosed. This represents a single-item mandatory disclosure with no quantified impacts provided.

26-02-2026

Aurinia Pharmaceuticals Inc. filed an 8-K on 2026-02-26 (AccNo: 0001600620-26-000015, Size: 357 KB) under Item 2.02 disclosing results of operations and financial condition. No quantitative financial metrics, revenue, earnings, guidance, or period-over-period comparisons are mentioned in the provided filing information. Sector is not specified.

26-02-2026

Soleno Therapeutics Inc filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details on the affected position, person involved, appointment or resignation status, reasons, and any quantitative metrics are NOT_DISCLOSED.

26-02-2026

Acushnet Holdings Corp. filed an 8-K on 2026-02-26 reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure with no detailed performance data available.

26-02-2026

Ecovyst Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001708035-26-000047), reporting under Item 2.02 for Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. This constitutes a multi-item voluntary disclosure of financial results. No specific quantitative financial metrics, comparisons, or details are disclosed in the filing summary provided.

26-02-2026

The company filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-072697), reporting under Item 3.02 Unregistered Sales of Equity Securities, Item 7.01 Regulation FD Disclosure, and Item 8.01 Other Events. This is a multi-item filing with no specific details on transaction sizes, financial impacts, share counts, or other quantitative metrics disclosed in the provided information. No positive or negative performance metrics, comparisons, or guidance changes are mentioned.

26-02-2026

Clear Channel Outdoor Holdings, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a standard disclosure for financial results with attached statements. No specific revenue, earnings, guidance, period-over-period changes, or other metrics are disclosed in the provided filing information.

26-02-2026

NexPoint Real Estate Finance, Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing Results of Operations and Financial Condition, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are disclosed in the provided information.

26-02-2026

Celsius Holdings, Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item informational filing typical for earnings releases.

26-02-2026

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. filed a Form 8-K on February 26, 2026, disclosing changes in its certifying accountant under Item 4.01. The filing also references Item 9.01 for financial statements and exhibits. No quantitative data, financial metrics, named entities beyond the registrant, or further details on the change are explicitly stated.

26-02-2026

News Corp filed a Form 8-K on February 26, 2026, reporting Other Events under Item 8.01 and attaching Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the other events, financial statements, or exhibits are disclosed in the filing summary. This is a multi-item informational filing with no quantified metrics or directional impacts provided.

26-02-2026

KBR, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001357615-26-000049, Size: 1 MB), reporting under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, guidance, or period-over-period metrics are disclosed in the provided filing details. This is a standard earnings-related disclosure with no quantified positive or negative performance indicators available.

26-02-2026

Kinetik Holdings Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the filing summary. This represents a standard mandatory disclosure for financial results without detailed performance data.

26-02-2026

26-02-2026

Nautilus Biotechnology, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001808805-26-000004) disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. Sector is not specified.

26-02-2026

Flowco Holdings Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073255), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. Sector details are not specified.

26-02-2026

Cactus, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition under Item 2.02, and financial statements and exhibits under Item 9.01. Specific details on the affected officer position, name, appointment or resignation, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the available information.

26-02-2026

InvenTrust Properties Corp. filed an 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. The filing size is 6 MB, suggesting possible attachments such as press releases or presentations, but no specific details, financial metrics, transactions, or events are disclosed in the provided information. No positive or negative metrics reported.

26-02-2026

Ellington Financial Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific quantitative metrics, comparisons, or guidance in the available information. No positive, negative, or flat performance indicators are detailed.

26-02-2026

Hormel Foods Corp /DE/ filed an 8-K on February 26, 2026 (AccNo: 0000048465-26-000018), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. Sector is not specified.

• ·Filing size: 541 KB
• ·Event Type: Financial Results
• ·Source: us_sec

26-02-2026

Integra LifeSciences Holdings Corp filed an 8-K on February 26, 2026, reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits provided under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the filing details provided. This appears to be a standard earnings-related disclosure without detailed performance data available.

26-02-2026

Zura Bio Ltd filed a Form 8-K on 2026-02-26 disclosing entry into a Material Definitive Agreement under Item 1.01, Results of Operations and Financial Condition under Item 2.02, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01 (AccNo: 0001104659-26-019827, size 744 KB). This is a multi-item filing covering a material transaction alongside financial updates, but specific details including transaction value, financial metrics, and performance changes are NOT_DISCLOSED. No quantitative impacts or period-over-period comparisons are available.

• ·Multi-item 8-K filing
• ·Sector: NOT_DISCLOSED

26-02-2026

VSE Corp filed an 8-K on February 26, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, margins, period-over-period changes, or other financial metrics are disclosed in the provided filing summary. This is an informational disclosure of financial results without quantified details.

26-02-2026

Trulieve Cannabis Corp. filed a Form 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. This is a multi-item filing typical for earnings releases with no specific revenue, earnings, or other metrics disclosed. No positive, negative, or flat performance indicators are provided in the filing summary.

26-02-2026

International Paper Co /NEW/ filed an 8-K on February 26, 2026, reporting under Item 7.01 Regulation FD Disclosure. No specific financial metrics, transactions, events, or quantitative data are explicitly stated in the provided filing information. This is a voluntary disclosure with no details on positive or negative impacts available.

26-02-2026

American Bitcoin Corp. filed an 8-K on February 26, 2026, reporting Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific financial metrics, revenue, earnings, or period-over-period comparisons are disclosed in the provided filing information. This appears to be an informational disclosure of quarterly or annual results without detailed quantitative data available.

26-02-2026

Ducommun Inc./DE/ filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011949, Size: 754 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing focused on financial results with no specific quantitative metrics, period-over-period changes, positive or negative performance indicators disclosed in the provided information. No revenue, earnings, guidance, or balance sheet details are mentioned.

26-02-2026

Enovis Corp filed a Form 8-K on February 26, 2026 (AccNo: 0001420800-26-000008, Size: 637 KB), reporting Results of Operations and Financial Condition under Item 2.02 and providing Financial Statements and Exhibits under Item 9.01. This is a standard earnings-related disclosure for a US equity market company. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing summary.

26-02-2026

Certara, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, guidance, or quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance numbers.

26-02-2026

Eos Energy Enterprises, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-011958), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics were disclosed in the provided filing information.

26-02-2026

Nuvalent, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-073304, Size: 378 KB), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing information.

26-02-2026

United Parks & Resorts Inc. filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with exhibits attached.

26-02-2026

Perrigo Co plc filed an 8-K on February 26, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing details. This is a standard multi-item voluntary disclosure for financial results with no directional performance indicators available.

26-02-2026

CommScope Holding Company, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-073295), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a standard earnings-related disclosure, but specific revenue, earnings, guidance, or other financial metrics are NOT_DISCLOSED in the provided filing details. No positive or negative performance indicators, period-over-period comparisons, or balance sheet impacts are mentioned.

26-02-2026

Wolverine World Wide Inc. (/DE/) filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011956, Size: 690 KB), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item, voluntary earnings-related filing typical for US public companies. No specific quantitative financial metrics, period-over-period comparisons, guidance, or other numerical data are provided in the filing description.

26-02-2026

NCR Voyix Corp filed a Form 8-K on February 26, 2026 (AccNo: 0000070866-26-000005), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing announces financial results, but specific revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED. No quantitative metrics, balance sheet effects, or outlook revisions are provided in the available information.

26-02-2026

Warby Parker Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001504776-26-000003), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely announcing quarterly or annual financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information.

26-02-2026

Krispy Kreme, Inc. filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, period-over-period comparisons, or other financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.

26-02-2026

TopBuild Corp filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific quantitative financial metrics, period-over-period comparisons, guidance, or other details are disclosed in the provided filing information.

26-02-2026

J M Smucker Co filed an 8-K on February 26, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. This is a multi-item filing with no specific revenue, earnings, guidance, or other quantitative financial metrics disclosed in the provided information. No positive or negative performance details, period-over-period comparisons, or strategic updates are mentioned.

26-02-2026

Nexstar Media Group, Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. No quantitative financial metrics, period-over-period comparisons, revenue, earnings, guidance, or other specific numbers are mentioned in the provided filing details. This is a standard mandatory disclosure for financial results without detailed performance data available.

26-02-2026

Warner Bros. Discovery, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely related to an earnings release or financial update. No specific financial metrics, guidance, transaction details, or quantitative data are disclosed in the provided filing summary.

26-02-2026

Kimbell Royalty Partners, LP filed an 8-K on February 26, 2026 (AccNo: 0001104659-26-020066, Size: 500 KB), disclosing Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing typical for financial results releases. No specific revenue, earnings, comparisons, positive or negative metrics, guidance, or other quantitative details are explicitly stated.

26-02-2026

Frontdoor, Inc. filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific financial metrics, period-over-period comparisons, guidance, or other quantitative details are provided in the filing summary. This appears to be a standard earnings-related disclosure with no disclosed positive or negative performance indicators.

26-02-2026

Ligand Pharmaceuticals Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0000886163-26-000003), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on financial results disclosure. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information.

26-02-2026

TG Therapeutics, Inc. filed a Form 8-K on 2026-02-26 reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were disclosed in the filing description. This is an informational earnings-related disclosure without quantified performance metrics.

26-02-2026

FRACTYL HEALTH, INC. filed a Form 8-K on 2026-02-26 reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing disclosing material non-public information with attached exhibits. No quantitative financial metrics, transactions, period-over-period comparisons, or specific events are detailed in the filing summary.

26-02-2026

BlackSky Technology Inc. filed an 8-K on February 26, 2026 (AccNo: 0001753539-26-000009), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet changes, guidance, or quantitative metrics were disclosed in the provided filing information. This is a multi-item mandatory filing typical for earnings releases, but lacks detailed financial data for impact assessment.

26-02-2026

Hilton Grand Vacations Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are mentioned in the provided filing details. All quantitative financial metrics are NOT_DISCLOSED.

26-02-2026

Tecnoglass Inc. filed an 8-K on February 26, 2026, under Item 2.02 reporting Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, margins, or other financial metrics are disclosed in the provided filing information. No positive, negative, or flat performance indicators are mentioned.

26-02-2026

Vital Farms, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details including the key position affected, appointment or resignation status, reason for change, and any financial metrics are NOT_DISCLOSED. No quantitative data, named executives, or scheduled events are provided in the available information.

26-02-2026

Middleby Corp filed an 8-K on February 26, 2026 (AccNo: 0000769520-26-000006), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. This is a standard earnings-related disclosure. No specific financial metrics, period-over-period changes, guidance, or other quantitative details are disclosed in the provided filing information.

26-02-2026

Phathom Pharmaceuticals, Inc. filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the filing summary. This is a standard voluntary disclosure for financial results, likely related to quarterly or annual earnings.

26-02-2026

Entrada Therapeutics, Inc. filed a Form 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were disclosed in the provided information. This is a multi-item filing focused on financial results announcement.

26-02-2026

Niagen Bioscience, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001386570-26-000003, Size: 162 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the core events, transactions, financial impacts, or exhibits provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons are disclosed.

26-02-2026

Akebia Therapeutics, Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing Results of Operations and Financial Condition, with Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, revenue, earnings, guidance, or other quantitative data are disclosed in the provided filing information. Sector details are not specified.

26-02-2026

Zai Lab Ltd filed an 8-K on February 26, 2026 (AccNo: 0001704292-26-000014), reporting under Item 2.02 Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no directional performance indicators available.

26-02-2026

D-Wave Quantum Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001907982-26-000022, Size: 7 MB), under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. This is a multi-item voluntary disclosure typical for earnings releases, but no specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics are available for balanced assessment.

26-02-2026

Teleflex Inc filed a Form 8-K on February 26, 2026, reporting results of operations and financial condition (Item 2.02), costs associated with exit or disposal activities (Item 2.05), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). This multi-item filing indicates quarterly financial results alongside restructuring or disposal-related costs, suggesting potential mixed performance with operational updates but added expenses. Specific revenue, earnings, cost amounts, guidance, or period-over-period changes are NOT_DISCLOSED.

26-02-2026

Bentley Systems Inc filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, or quantitative details are provided in the filing summary. This appears to be a standard earnings-related disclosure without disclosed positives, negatives, or flat performance indicators.

26-02-2026

GigaCloud Technology Inc filed a Form 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. This is a standard disclosure for financial results, likely related to quarterly or annual earnings. No specific revenue, earnings, guidance, or period-over-period metrics are detailed in the provided filing summary.

26-02-2026

Avanos Medical, Inc. filed an 8-K on February 26, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details, transaction values, financial metrics, positive or negative impacts, or comparisons were disclosed in the provided filing summary. This is a multi-item mandatory disclosure with no quantitative data available.

26-02-2026

Butterfly Network, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, period-over-period changes, or other quantitative metrics are disclosed in the provided filing information.

26-02-2026

Shift4 Payments, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. This is a standard voluntary earnings-related disclosure with no specific revenue, earnings, guidance, or other quantitative metrics detailed in the filing summary. No period-over-period comparisons, positive or negative changes, or operational details are provided.

26-02-2026

Shake Shack Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, guidance, or period-over-period metrics are disclosed in the provided filing details. This multi-item voluntary disclosure provides an informational update on operations without quantitative data for impact assessment.

26-02-2026

NovoCure Ltd filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing description. This is a standard voluntary disclosure of financial results with attached exhibits.

26-02-2026

Carlyle Group Inc. filed an 8-K on February 26, 2026 (AccNo: 0001527166-26-000006, Size: 3 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item, voluntary disclosure as Item 7.01 is not mandatory. No specific content details, financial metrics, transactions, or material events are disclosed in the provided filing summary.

26-02-2026

Hagerty, Inc. filed a Form 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, Item 7.01 for Regulation FD disclosure, and Item 9.01 for financial statements and exhibits. This is a multi-item filing announcing financial results, but specific revenue, earnings, or other quantitative metrics are NOT_DISCLOSED. No period-over-period comparisons, guidance, or balance sheet effects are provided in the filing description.

26-02-2026

Shenandoah Telecommunications Co/VA/ filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or period-over-period comparisons were disclosed in the filing summary. This is a standard earnings-related disclosure with all quantitative financial metrics NOT_DISCLOSED.

26-02-2026

Kairos Pharma, LTD. filed a Form 8-K on February 26, 2026 (AccNo: 0001493152-26-008116), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are disclosed in the provided filing summary. This appears to be a multi-item, likely voluntary disclosure with no quantified financial or operational impacts mentioned.

26-02-2026

PENN Entertainment, Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This represents a standard voluntary disclosure of quarterly or periodic financial results.

26-02-2026

Indivior PLC filed a Form 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item voluntary disclosure typical for earnings releases.

26-02-2026

Viridian Therapeutics, Inc. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet metrics, period-over-period changes, or guidance were disclosed in the provided filing information. This appears to be an earnings-related disclosure, but detailed financial data is NOT_DISCLOSED.

26-02-2026

ADTRAN Holdings, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, or other quantitative metrics were detailed in the provided filing information. This appears to be a standard earnings-related disclosure without extracted numerical data.

26-02-2026

Vistra Corp. filed a Form 8-K on 2026-02-26 under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item mandatory disclosure typical for earnings releases.

26-02-2026

Anika Therapeutics, Inc. filed an 8-K on February 26, 2026, disclosing results of operations and financial condition under Item 2.02 and an officer or director change under Item 5.02, with exhibits under Item 9.01. Specific details on the leadership change, including position affected, appointment or resignation status, reasons, and timing, are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or named individuals are provided in the available information.

26-02-2026

Aclaris Therapeutics, Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This represents a standard voluntary disclosure of financial results typically tied to an earnings release.

26-02-2026

Kymera Therapeutics, Inc. filed a Form 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard earnings-related disclosure with no quantitative metrics available.

26-02-2026

Eagle Point Income Co Inc. filed an 8-K on February 26, 2026, reporting solely under Item 8.01 Other Events. No details on the core event, financial impacts, transactions, metrics, or scheduled events are disclosed in the provided filing information. This is a voluntary disclosure with no quantitative data or directional implications mentioned.

26-02-2026

Nuveen Churchill Direct Lending Corp. filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, or quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance numbers available.

26-02-2026

C4 Therapeutics, Inc. filed a Form 8-K on February 26, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet changes, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed financial data available.

26-02-2026

Wave Life Sciences Ltd. filed an 8-K on 2026-02-26 furnishing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, or period-over-period comparisons were disclosed in the provided filing information. Sector not specified.

26-02-2026

Lantheus Holdings, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-073439), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics were explicitly stated in the filing information provided.

26-02-2026

Installed Building Products, Inc. filed an 8-K on 2026-02-26 reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure typical for earnings releases. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information.

26-02-2026

Cheniere Energy Partners, L.P. filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, or period-over-period comparisons are detailed in the provided filing metadata. This appears to be a standard earnings-related disclosure without quantified metrics available.

26-02-2026

E.W. SCRIPPS Co filed an 8-K on February 26, 2026 (AccNo: 0000832428-26-000006), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements and exhibits (Item 9.01). Specific details on the officer change including key position affected, appointment or resignation status, reason, or timing are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or other numerical data are disclosed.

26-02-2026

Cognizant Technology Solutions Corp filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or impacts are provided in the available information. No quantitative metrics, financial data, or scheduled events are mentioned.

26-02-2026

Vera Therapeutics, Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073421, Size: 696 KB), reporting under Item 2.02 Results of Operations and Financial Condition, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet effects, guidance, period-over-period comparisons, or other quantitative financial metrics were disclosed in the provided filing details. This is a multi-item, mandatory disclosure typical for earnings releases, but lacks detailed data for impact assessment.

26-02-2026

Thryv Holdings, Inc. filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other financial metrics are disclosed in the provided information. This is a multi-item voluntary filing typical for earnings announcements.

26-02-2026

Payoneer Global Inc. filed an 8-K on 2026-02-26 under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period changes, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no directional financial data available.

26-02-2026

Collegium Pharmaceutical, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011990), under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing announces financial results, but no specific revenue, earnings, guidance, or other quantitative metrics are disclosed. No positive or negative performance indicators, period-over-period comparisons, or balance sheet details are provided.

26-02-2026

Crescent Biopharma, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001628280-26-011988, Size: 319 KB), disclosing results of operations and financial condition under Item 2.02 along with financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were provided in the filing summary. This represents a standard voluntary earnings-related disclosure with no directional financial metrics disclosed.

26-02-2026

Bread Financial Holdings, Inc. filed an 8-K on February 26, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific events, transactions, financial metrics, or quantitative data are disclosed in the filing summary provided. Critical details such as core events, dollar values, or performance metrics are NOT_DISCLOSED.

26-02-2026

Rhythm Pharmaceuticals, Inc. filed an 8-K on 2026-02-26 reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a multi-item filing focused on financial results disclosure.

26-02-2026

ACM Research, Inc. filed an 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information.

• ·Accession Number: 0001628280-26-011998
• ·Filing size: 613 KB
• ·Sector: NOT_DISCLOSED

26-02-2026

Intellia Therapeutics, Inc. filed an 8-K on February 26, 2026, under Item 2.02 reporting results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other financial metrics are disclosed in the provided filing information. This is a standard disclosure for financial results with no detailed quantitative data available.

26-02-2026

Cars.com Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-073457), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were detailed in the provided filing information. This is a standard earnings-related disclosure without quantified metrics.

26-02-2026

Pulmatrix, Inc. filed an 8-K on February 26, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits provided under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or other quantitative financial data are disclosed in the provided filing information. This appears to be an informational earnings-related disclosure without detailed performance metrics available.

26-02-2026

PROCEPT BioRobotics Corp filed an 8-K on February 26, 2026, reporting under Item 7.01 Regulation FD Disclosure. No specific events, transactions, financial metrics, positive or negative changes, or other details are explicitly stated in the provided filing information. All quantitative data and impacts are NOT_DISCLOSED.

26-02-2026

Perimeter Solutions, Inc. filed a Form 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a standard earnings-related disclosure. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative financial metrics are explicitly stated in the provided filing information.

26-02-2026

Matador Resources Co filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the attached exhibits are disclosed in the provided filing summary. No financial metrics, transactions, or directional impacts are mentioned.

26-02-2026

USA TODAY Co., Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001579684-26-000008), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This multi-item filing represents a standard voluntary earnings release with no specific revenue, earnings, balance sheet effects, guidance, or period-over-period comparisons provided in the excerpt. Critical quantitative data and operational details remain NOT_DISCLOSED.

26-02-2026

Victory Capital Holdings, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is an informational filing with no quantified positive or negative impacts mentioned.

26-02-2026

ACI Worldwide, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, nature of the change, financial metrics, or any quantitative data are disclosed in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

26-02-2026

Viatris Inc filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 2.05 (Costs Associated with Exit or Disposal Activities), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing discloses financial results alongside costs related to exit or disposal activities, suggesting potential restructuring, but no specific metrics, amounts, or performance details are provided. This is a multi-item mandatory disclosure with no quantified positive or negative impacts visible.

26-02-2026

vTv Therapeutics Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001641489-26-000005, Size: 4 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the disclosed information, events, financial metrics, or exhibits provided. No positive or negative metrics are mentioned.

26-02-2026

Heron Therapeutics, Inc. filed an 8-K on February 26, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. This is a multi-item filing focused on financial results disclosure. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative data were detailed in the filing summary provided.

26-02-2026

Aquestive Therapeutics, Inc. filed a Form 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure, indicating a voluntary release of potentially material non-public information, with exhibits attached under Item 9.01. No quantitative financial metrics, transaction details, period-over-period comparisons, or specific events are disclosed in the filing metadata. This is a multi-item informational filing with no directional financial impact evident.

26-02-2026

Delcath Systems, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition as part of its financial results announcement. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were mentioned in the provided filing information. All quantitative metrics and further details are NOT_DISCLOSED.

26-02-2026

Picard Medical, Inc. filed a Form 8-K on February 26, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details on the disclosed information, financial metrics, transactions, or exhibits are provided in the filing summary. The disclosure appears informational with no quantified positive or negative impacts explicitly stated.

• ·Accession Number: 0001829126-26-001652
• ·File Size: 205 KB

26-02-2026

MannKind Corp filed an 8-K on February 26, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, with Item 9.01 attaching Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons are detailed in the provided filing information. This represents a standard mandatory disclosure for financial results without quantified metrics available.

26-02-2026

Novavax Inc filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, balance sheet details, or period-over-period comparisons are disclosed in the provided filing information. This is an informational earnings-related disclosure with no quantifiable positive or negative indicators available.

26-02-2026

Loar Holdings Inc. filed a Form 8-K on 2026-02-26 disclosing Item 2.02 Results of Operations and Financial Condition. No specific financial metrics, period-over-period comparisons, or quantitative data such as revenue, earnings, or guidance are explicitly stated in the provided filing information. No positive, negative, or flat performance indicators are mentioned.

26-02-2026

Golden Matrix Group, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001477932-26-001050, Size: 185 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, financial metrics, or quantitative data disclosed in the provided summary. No positive, negative, or flat performance metrics are mentioned.

26-02-2026

Vericel Corp filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-012003, Size: 378 KB), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period changes, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard mandatory disclosure for financial results without detailed outcomes available.

• ·AccNo: 0001628280-26-012003
• ·File Size: 378 KB
• ·Sector: not specified
• ·Event Type: Financial Results

26-02-2026

Roadzen Inc. filed an 8-K on 2026-02-26 reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement, transaction terms, parties, financial impacts, or metrics are disclosed. This is a multi-item mandatory disclosure with no quantitative data provided.

• ·Filing Accession Number: 0001493152-26-008128
• ·Filing Size: 319 KB

26-02-2026

Rackspace Technology, Inc. filed a Form 8-K on 2026-02-26 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. This is a multi-item mandatory filing for financial results announcement. No specific financial metrics, period-over-period changes, guidance, or quantitative data are disclosed in the provided filing information.

26-02-2026

MVB Financial Corp filed an 8-K on 2026-02-26 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the agreement, obligation size, terms, or financial impacts are disclosed in the provided information. This represents a multi-item mandatory disclosure with potential balance sheet implications, but lacks quantification.

26-02-2026

CACI International Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed in the provided filing summary. This appears to be a multi-item informational filing with no quantified metrics or directional impacts mentioned.

26-02-2026

Disc Medicine, Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This constitutes a standard earnings-related disclosure without quantified metrics.

26-02-2026

Edgewise Therapeutics, Inc. filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or other quantitative financial data are mentioned in the filing description. This appears to be a standard voluntary quarterly financial results disclosure.

26-02-2026

Burford Capital Ltd filed an 8-K on February 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but specific metrics, transaction details, or performance data are NOT_DISCLOSED. No positive or negative financial changes, guidance, or comparisons are provided in the available information.

26-02-2026

Universal Health Services Inc filed an 8-K on 2026-02-26 disclosing Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits), indicating a financial results announcement. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided information. No positive or negative performance details, period-over-period comparisons, or material events with dollar values are mentioned.

26-02-2026

Hertz Global Holdings, Inc. filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative financial data are explicitly stated in the provided filing details. This appears to be a standard earnings-related disclosure without detailed metrics available.

26-02-2026

Arrow Financial Corp filed a Form 8-K on February 26, 2026 (AccNo: 0000717538-26-000030, Size: 48 MB), reporting under Item 1.01 entry into a material definitive agreement, Item 7.01 Regulation FD disclosure, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No quantitative metrics, transaction details, financial impacts, or period-over-period comparisons are disclosed. The large filing size suggests substantial exhibits, likely including the agreement text.

26-02-2026

Playtika Holding Corp. filed an 8-K on February 26, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no quantitative data available.

26-02-2026

CRA International, Inc. filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, or guidance details are provided in the filing summary. This appears to be a standard earnings-related disclosure without quantified data available.

26-02-2026

Freshworks Inc. filed an 8-K on February 26, 2026, under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or exhibits are disclosed in the filing summary provided. This appears to be a multi-item voluntary disclosure with no quantitative financial metrics or directional impacts mentioned.

26-02-2026

Sunoco LP filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-073531), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely disclosing financial results, but no specific revenue, earnings, or other quantitative metrics are mentioned. No positive or negative performance indicators, comparisons, or guidance changes are provided in the filing details.

26-02-2026

Bank of New York Mellon Corp filed an 8-K on February 26, 2026, reporting solely under Item 8.01 Other Events. No details on the specific event, financial impacts, transactions, or metrics are disclosed in the provided filing information. No positive or negative metrics are mentioned.

26-02-2026

Marcus Corp filed an 8-K on February 26, 2026, under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative financial metrics are mentioned in the filing details provided. This appears to be a standard earnings-related disclosure without detailed performance data available.

26-02-2026

SIRIUS XM HOLDINGS INC. filed a Form 8-K on 2026-02-26 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the filing summary. This is a multi-item informational filing with no quantified financial metrics, positive or negative developments, or performance comparisons provided.

26-02-2026

Runway Growth Finance Corp. filed a Form 8-K on February 26, 2026, under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, financial metrics, numerical values, or period-over-period comparisons disclosed in the provided filing summary. Critical event details and exhibits are NOT_DISCLOSED.

26-02-2026

MSA Safety Inc filed an 8-K on February 26, 2026, under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other event, financial metrics, transaction values, or impacts are disclosed in the filing summary. This appears to be a multi-item informational filing with attached exhibits.

26-02-2026

U S PHYSICAL THERAPY INC /NV filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details on the officer, position, reason for change, or any impacts are NOT_DISCLOSED.

• ·Filing Accession Number: 0001140361-26-006882
• ·File size: 1 MB
• ·Sector: NOT_DISCLOSED

26-02-2026

Kindly MD, Inc. filed an 8-K on February 26, 2026, disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01). The filing also covers unregistered sales of equity securities (Item 3.02), departure or election of directors/officers and compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific transaction details, financial metrics, parties, or values are disclosed.

26-02-2026

Manhattan Associates Inc filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.